CME

Inflamed and Untamed: Managing the Progression of Diabetic Eye Disease

Inflamed and Untamed: Managing the Progression of Diabetic Eye Disease

This activity is supported by an educational grant from Allergan, Inc.

Overview

Author(s)/Faculty: Rishi P. Singh, MD; Jay S. Duker, MD; Andrew A. Moshfeghi, MD, MBA
Source: Healio - Ophthalmology Education Lab
Type: LectureArticles/Items: 5
Release Date: 3/1/2017Expiration Date: 2/28/2018
Credit Type: CMENumber of Credits: 1
Cost: FreeProvider: Vindico Medical Education
Diabetic retinopathy (DR) is a major cause of blindness, with an estimated 4.2 million people over the age of 40 affected by this condition within the United States. Loss of vision is most frequently due to diabetic macular edema (DME), a consequence of DR, but it can also be a direct result of DR. Inflammation plays an important role in the pathogenesis of DME, and recent advances in the understanding of the underlying pathophysiology of the disease have led to the development of therapies for DME and DR. With the observed continued rise in the prevalence of DR, it is imperative that optimal surgical and medical therapies are integrated into everyday practice for the effective management of diabetic eye disease. Within this CME activity, experts discuss the underlying role of inflammation in the pathogenesis of DR and DME and provide insight into the management of progressive diabetic eye disease as well as guidance for the effective management of patients with diabetic eye disease through case presentations.

CME Information

page 1 of 8